Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study

被引：0
|
作者：
Yuan Zong
Jiajia Yuan
Zhi Peng
Ming Lu
Xicheng Wang
Lin Shen
Jun Zhou
机构：
[1] Peking University Cancer Hospital & Institute,Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Gastrointestinal Oncology
来源：
Journal of Cancer Research and Clinical Oncology | 2021年 / 147卷
关键词：
Advanced pancreatic ductal adenocarcinoma; Chemotherapy; Nab-paclitaxel; S-1; Gemcitabine; Objective response rate;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1529 / 1536
页数：7
相关论文
共 50 条
  • [1] Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study
    Zong, Yuan
    Yuan, Jiajia
    Peng, Zhi
    Lu, Ming
    Wang, Xicheng
    Shen, Lin
    Zhou, Jun
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2021, 147 (05) : 1529 - 1536
  • [2] Efficacy and Safety of Nab-Paclitaxel Plus S-1 versus Nab-Paclitaxel Plus Gemcitabine for First-Line Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma
    Zong, Yuan
    Peng, Zhi
    Wang, Xicheng
    Lu, Ming
    Shen, Lin
    Zhou, Jun
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 12657 - 12666
  • [3] Efficacy and toxicity comparison of nab-paclitaxel plus S-1 and nab-paclitaxel plus gemcitabine as first-line chemotherapy for metastatic pancreatic cancer
    Guo Xi
    Xu Yaolin
    Ji Yuan
    Fan Yue
    Wang Dansong
    Jin Dayong
    Zhuang Rongyuan
    Wu Lili
    Lou Wenhui
    Zhou Yuhong
    Department of Medical Oncology
    Department of General Surgery
    Department of Pathology
    Department of Traditional Chinese Medicine
    Department of Radiotherapy
    胰腺病学杂志（英文）, 2020, 03 (01) : 35 - 41
  • [4] Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer: a multicenter, randomized, phase II study
    Jin, Min
    Liu, Hong-Li
    Xue, Jun
    Ma, Hong
    Liu, Jun-Li
    Lin, Zhen-Yu
    Wang, Jing
    Bao, Le-Qun
    Luo, Zhi-Guo
    Yu, Xiong-Jie
    Li, Shuang
    Hu, Jian-Li
    Zhang, Tao
    ONCOLOGIST, 2024, 29 (10) : e1406 - e1418
  • [5] Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinoma
    Rogers, Jane E.
    Mizrahi, Jonathan D.
    Xiao, Lianchun
    Mohindroo, Chirayu
    Shroff, Rachna T.
    Wolff, Robert
    Varadhachary, Gauri R.
    Javle, Milind M.
    Overman, Michael
    Fogelman, David R.
    Raghav, Kanwal P. S.
    Pant, Shubham
    McAllister, Florencia
    CANCER MEDICINE, 2020, 9 (15): : 5406 - 5415
  • [6] Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis
    Kang, Jihoon
    Hwang, Inhwan
    Yoo, Changhoon
    Kim, Kyu-pyo
    Jeong, Jae Ho
    Chang, Heung-Moon
    Lee, Sang Soo
    Park, Do Hyun
    Song, Tae Jun
    Seo, Dong Wan
    Lee, Sung Koo
    Kim, Myung-Hwan
    Hong, Seung-Mo
    Shin, Sang Hyun
    Hwang, Dae Wook
    Song, Ki Byung
    Lee, Jae Hoon
    Kim, Song Cheol
    Ryoo, Baek-Yeol
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (04) : 732 - 741
  • [7] Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study
    Shuling Chen
    Jiaxin Li
    Aoran Dong
    Zelong Liu
    Meiyan Zhu
    Meng Jin
    Guangyan Wei
    Shuang Wu
    Yan Wang
    Yong Chen
    Zhenwei Peng
    Journal of Hematology & Oncology, 16
  • [8] Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study
    Chen, Shuling
    Li, Jiaxin
    Dong, Aoran
    Liu, Zelong
    Zhu, Meiyan
    Jin, Meng
    Wei, Guangyan
    Wu, Shuang
    Wang, Yan
    Chen, Yong
    Peng, Zhenwei
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2023, 16 (01)
  • [9] Efficacy of S-1 in second-line chemotherapy after nab-paclitaxel plus gemcitabine for patients with advanced pancreatic cancer
    Iede, Kiyotsugu
    Yamada, Terumasa
    Kato, Ryo
    Ueda, Masami
    Tsuda, Yujiro
    Nakashima, Shinsuke
    Ohta, Katsuya
    Matsuyama, Jin
    Ikenaga, Masakazu
    Tominaga, Shusei
    CANCER REPORTS, 2020, 3 (02)
  • [10] The Efficacy and Safety of PD-1 Inhibitors Combined with Nab-Paclitaxel Plus Gemcitabine versus Nab-Paclitaxel Plus Gemcitabine in the First-Line Treatment of Advanced Pancreatic Cancer: A Retrospective Monocentric Study
    Zhang, Feng
    Wang, Yuyang
    Yang, Fangfang
    Zhang, Yuming
    Jiang, Man
    Zhang, Xiaochun
    CANCER MANAGEMENT AND RESEARCH, 2022, 14 : 535 - 546
12345